Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06823167 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
A Phase 1 study of Hematologic Malignancies and Solid Malignancies, sponsored by Immunome.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 117
- Enrollment target
- 10
- Study locations
NCT06823167: Recruiting Phase 1 study of Hematologic Malignancies and Solid Malignancies, sponsored by Immunome.
NCT06823167 is a Phase 1 study of Hematologic Malignancies and Solid Malignancies that is actively recruiting participants, run by Immunome. The registered enrollment target is 117 participants, below the 2,709-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (96% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06823167, a Phase 1 study of Hematologic Malignancies and Solid Malignancies, is actively recruiting participants, sponsored by Immunome.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 117 participants
- Enrollment target
- 10
- Study locations
Study Summary
IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.
Primary Outcome
Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 5.0, including serious adverse events (SAEs), AEs of interest (AEI), AEs leading to discontinuation, and deaths
Conditions Studied
Interventions
- BIOLOGICAL IM-1021
Study Locations (10)
Michigan
- University of Michigan - Ann Arbor
- START Midwest - Grand Rapids
Texas
- MD Anderson Cancer Center - Houston
- NEXT Oncology - Irving
California
- City Of Hope - Duarte
Connecticut
- Yale University Medical Center - New Haven
Georgia
- Emory Winship Cancer Institute - Atlanta
Nebraska
- University of Nebraska Medical Center - Omaha
Ohio
- Gabrail Cancer Center - Canton
Tennessee
- Sarah Cannon Research Institute - Oncology Partners - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2025-02-26 |
| Est. Completion | 2029-02 |
| Phase | Phase 1 |
What NCT06823167 shows while recruiting
NCT06823167 is an interventional study that assigns participants to a tested intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, below the 2,709-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Hematologic Malignancies appearing as the primary indexed condition, and to 1 intervention - of which IM-1021 is the first listed.
NCT06823167 lists 10 locations in 8 states (Michigan, Texas, California).
Frequently Asked Questions
What is clinical trial NCT06823167 about?
NCT06823167 is a clinical study titled "A Phase 1 Study of IM-1021 in Participants With Advanced Cancer". IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.
What is the current status of trial NCT06823167?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2025-02-26. Estimated completion is 2029-02.
What conditions does trial NCT06823167 study?
This clinical trial studies the following conditions: Hematologic Malignancies, Solid Malignancies.
What interventions are being tested in trial NCT06823167?
The interventions under investigation include: IM-1021 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06823167?
This trial is sponsored by Immunome, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06823167 being conducted?
This trial has 10 study locations across California, Connecticut, Georgia, Michigan, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06823167's enrollment target sits among peer trials
117 16th of 45 higher than 30 of 45 other Hematologic Malignancies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematologic Malignancies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RECRUITING · Phase 1
-
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
RECRUITING · Phase 1
-
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RECRUITING · Phase 1
-
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03539822 · 117 participants · Phase 1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI